

2023 Annual Sickle Cell Disease Research

Agenda

August 14-16, 2023


9:00 AM - 5:00 PM EDT

A Hybrid Meeting

William H. Natcher Conference Center

Building 45, National Institutes of Health





DAY 1 – Monday, August 14th

9:00 am-5:05 pm	MONDAY MEETING TIME (EDT) August 14 th
9:00-9:10 am	Welcome and Announcements Dr. Julie Panepinto, Director, Division of Blood Diseases & Resources, National Heart, Lung and Blood Institute, NIH Dr. Pankaj Qasba, Division of Blood Diseases & Resources, National Heart, Lung and Blood Institute, NIH
9:10 am-12:20 pm	SYMPOSUIM 1
9:10 am-12:20 pm	Curative Therapies for SCD- I Chair: Dr. Lakshmanan Krishnamurti, Yale University Parental Perspective on the Risk of Infertility and Fertility Preservation Options for Children and Adolescents With SCD Considering HCT Dr. Cynthia B. Sinha, Emory University Normalization of Cerebral Hemodynamics After HSCT in Children with SCD Dr. Monica L. Hulbert, Washington University Multimodal Phenotyping and Correlates of Pain Following Hematopoietic Cell Transplant in Children with Sickle Cell Disease Dr. Nitya Bakshi, Emory University Reduction in Vaso-Occlusive Events Following Stem Cell Transplantation in Patients with SCD Dr. Alexis Leonard, St. Jude Children's Research Hospital Outcomes Following Posttransplant Virus-specificT-cell Therapy in Patients with SCD Dr. Hannah Kinoshita, Children's National Hospital Long-Term Organ Function After HCT for SCD: A Report from the Sickle Cell Transplant Advocacy and Research Alliance Dr. Elizabeth Stenger, Emory University
	Increased Incidence of Hematologic Malignancies in SCD After HCT in Adults With Graft Failure and Mixed Chimerism Dr. Rialnat A. Lawal, National Heart, Lung and Blood Institute, NIH

	Secondary Neoplasms After HCT for SCD
	Dr. Mary Eapen, Medical College of Wisconsin
	Formale Demonducative Health Outcomes After HCT for CCD: le Deduced Interesity Potter
	Female Reproductive Health Outcomes After HCT for SCD: Is Reduced Intensity Better Than Myeloablative Conditioning?
	Dr. Lillian Meacham, Emory University
	, ,
10:40-10:50 am	BREAK
	Curative Therapies for SCD- II (Gene Therapy/Editing) Chair: Dr. Punam Malik, Cincinnati Children's Hospital
	Gene Therapy Using an Antisickling Lentivirus Vector and the Use of Non Toxic Conditioning Dr. John Tisdale, National Heart, Lung and Blood Institute, NIH
	In Vivo Gene Editing for SCD
40.50	Dr. Hans-Peter Kiem, The Fred Hutch Cancer Research Centre
10:50 am -12:20 pm	Cono Editing for Sickle Call Disease
	Gene Editing for Sickle Cell Disease Dr. Mitch Weiss, St Jude Children's Hospital
	Base Editing to increase Fetal Hemoglobin
	Dr. Annarita Miccio, Imagine Institute, Paris
	Prime Editing Beta Sickle Hemoglobin
	Dr. Gregory Newby, Johns Hopkins University
12:20-1:05	LUNCH
1:05-5:05 pm	SYMPOSIUM 2
1:05-2:50 pm	Updates on Trials on SCD
1:05-1:30 pm	Proof-of-concept Study of Nicotinamide and Oral THU/Decitabine to Treat High Risk Sickle Cell Disease
	Dr. Yogen Saunthararajah, Cleveland Clinic, Case Western Reserve University
	CRISPR SCD Gene Editing Trial Update
	Dr. Mark Walters, University of California
1:30-2:10 pm	
	Post-transcriptional Silencing of BCL11A Using a Lentivirus shmiR Vector, the Phase 2
	GRASP Trial
	Dr. David Williams, Boston Children's Hospital
	A Phase IIb Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess
2:10-2:50 pm	the <u>Safety</u> , <u>Tolerability</u> , and <u>Efficacy</u> of <u>Rio</u> ciguat in Patients with <u>Sickle Cell Disease</u> : The
	Primary Results of the STERIO-SCD Trial
	Dr. Mark Gladwin, University of Maryland School of Medicine Dr. Kaleab Abebe, University of Pittsburgh School of Medicine
	Pr. Naicas Asese, Offiversity of Fittsburgh school of Medicine

2:50 – 3:00 pm	BREAK
3:00-3:20 pm	Enhancing Emergency Department Care for Children with SCD: An Implementation Science Approach Dr. David Brousseau, Nemours Children's Health, Delaware & Sidney Kimmel Medical College at Thomas Jefferson University
3:20-4:05 pm	Making the Case for Palliative Care in Sickle Cell Disease Dr. Eberechi Nkele Nwogu-Onyemkpa, Baylor College of Medicine Dr. Stephanie Kiser, Harvard University Dr. Ashley Allen, Duke University
4:05-4:25 pm	HIV-1 Infection in Sickle Cell Disease Dr. Sergei Nekhai, Howard University
4:25-4:45 pm	Panel of Multiple Urinary Biomarkers for the Early Detection of Chronic Kidney Disease in Sickle Cell Anemia SCORE: Dr. Marina Jerebtsova, Howard University
4:45-5:05 pm	Stepping Up Into Adult Care: An Update on the ST3P UP Study Dr. Ify Osunkwo, Novo Nordisk Rare Disease
5:05 pm	MEETING ADJOURNED FOR THE DAY



DAY 2 – Tuesday, August 15th

9:00 am-5:15 pm	TUESDAY MEETING TIME (EDT)-August 15 th
9:00-9:05 am	Welcome and Announcements
9:05-11:25 am	SYMPOSIUM 3
9:05-10:35 am	Global SCD:
	SCD: Indian Scenario
	Dr. Rabindra Kumar Jena, SCB Medical College & Hospital, Cuttack-India
	Implementation of Massive National SCD Programme in Indian Health Care System;
	Challenges and Solutions
	Dr. Bontha V. Babu, National Institute for Implementation Research on NCDs-Jodhpur, India
	Translation of Research to Improve Health in Sickle Cell Disease: Anemia, Genomics, and Gene Therapy
	Dr. Julie Makani, MUHAS, Dar-es-Salaam, Tanzania, Africa
	Recent Progress in Brazilian SCD
	Dr. Carla Dinardo, Fundação Pró-Sangue São Paulo Hemocenter and University of São Paulo School of Medicine- Brazil
10:25-10:35 am	Q & A
10:35-10:55 am	The Global Gene Therapy Initiative (GGTI): Sickle Cell Disease as a Global Community Dr. Jennifer Adair, Fred Hutchinson Cancer Center
10:55-11:05 am	BREAK
11:05-11:25 am	H3 Africa The SickleGenAfrica Cohort: Hemolysis Cytoprotective Phenotypes
	Dr. Solomon Ofori-Acquah, University of Ghana
11:25 am-5:00 pm	SYMPOSIUM 4
	Building a TRIAD to Improve Transition in SCD
	Co-chairs: <i>Dr. Payal Desai,</i> Wake Forest School of Medicine <i>and Dr. Elna Saah,</i> Emory
	University School of Medicine
	The Issues Around Transition
11:25 am-12:55 pm	Peggy Magnus, MHS and Dr. Patience White- The Got Transition Team
	Practical Implementation Standard of Care in Transition
	Dr. Elna Saah, Emory University School of Medicine
	TRIAD Fishbowl
	Engagement Discussion Between Pediatric/Adults/CBO: What Barriers are Identified to
	Building a TRIAD? Drs. Ramona Lawrence, India Sisler, Jane Hankins, & Wanda Witten-Shurney- Community
	Based Organization
12:55-1:40 pm	LUNCH

1:40-2:00pm	ASH Research Collaborative: Where are we now? Dr. Charles Abrams, University of Pennsylvania Dr. Alexis Thompson, Children's Hospital of Philadelphia
2:00-3:00pm	A Study of Sickle Cell Disease and Spleen Function through Modeling and Experiments Integrating In Silico, In Vitro, Ex Vivo and In Vivo Approaches Dr. George Karniadakis, Brown University Dr. Pierre Buffet, Institute Pasteur Dr. Ming Dao, MIT
3:00-3:10 pm	BREAK
3:10-3:50 pm	TOPMed Updates Unbiased Plasma Proteomics Analysis Uncovers Potential Biomarkers for Renal Disease and Pulmonary Hypertension in Patients With Sickle Cell Disease. Dr. Allison Ashley-Koch, Duke University Blood Gene Expression Profile of Sickle Cell Trait Dr. Mari Johnson, The Fred Hutch Cancer Research Centre
3:50-4:10 pm	Development of Biomarkers for Acute and Chronic Pain in SCD Using Omics Dr. Vivien Sheehan, Emory University
4:10-4:30 pm	Endothelialized Microfluidic Assays for Emerging Therapies in Sickle Cell Disease Dr. Umut Gurkan, Case Western Reserve University
4:30-4:50 pm	Cost-Effectiveness of Gene Therapy for Sickle Cell Disease: Accounting for Impacts Beyond Healthcare Dr. Scott Ramsey, Hutchinson Institute for Cancer Outcomes Research
4:50-5:10 pm	Heterogeneity of Magnetic Susceptibility, and Correspondingly, Oxygen Saturation, of RBC in Non-Transfused, SS, SC, And SB+ Patients Dr. Jeffrey Chalmers, Ohio State University
5:10 pm	MEETING ADJOURNED FOR THE DAY



DAY 3 – Wednesday, August 16th

9:00 am-5:00 pm	WEDNESDAY MEETING TIME (EDT)-August 16 th
9:00-9:05 am	Welcome and Announcements
9:05 am-1:10 pm	SYMPOSIUM 5
9:05-9:25am	Leveraging the SCDIC Registry Population and Infrastructure for Ancillary Studies Dr. Tabitha Hendershot, RTI International
9:25-9:45am	REAL ANSWERS: A Target Trial Emulation Study Built on the SCDIC Registry Data Architecture Dr. Jeffrey Glassberg, Icahn School of Medicine at Mount Sinai
9:45-10:00 am	Program: Inviting Blood Related Clinical Trials to NHLBI Dr. Andrei Kindzelski, Division of Blood Diseases & Resources, National Heart, Lung and Blood Institute, NIH
10:00- 11:30	National Alliance of Sickle Cell Centers Consensus Recommendations for Screening for People Living with Sickle Cell Disease Co-chairs: Dr. Julie Kanter, University of Alabama, Birmingham and Dr. Deepa Manwani, The Children's Hospital at Montefiore
	Consensus Recommendations for Children with SCD ages 0-2 Dr. Deepa Manwani, The Children's Hospital at Montefiore Consensus Recommendations for Children and adolescents with SCD ages 2-18 Dr. Melissa Frei-Jones, South Texas Comprehensive Sickle Cell Program
	Consensus Recommendations for Adults with SCD Dr. Andrew O'Brien, Indiana Lifespan Sickle Cell Center at Indiana University Health
11:30:11:40	BREAK
11:40 am-1:10 pm	Integrative Interventions Targeting Peripheral and Central Mechanisms of Pain in SCD Co-chairs: Dr. Kalpna Gupta, and Dr. Shiu-Lin Tsai Disease Modifying and Nociceptive Mechanisms Underlying Sickle Cell Pain. Promising Interventions Waiting for Clinical Translation Dr. Kalpna Gupta, University of California Acupuncture for Pediatric Sickle Cell Pain Management: A Promising Non-Opioid Therapy
	Dr. Shiu-Lin Tsai, Columbia University Musculoskeletal Pain in SCD: Underlying Mechanisms and Challenges for Treatment Dr. Jahnavi Gollamudi, University of Cincinnati Music-Based Interventions for Pain Dr. Sonya Wang, University of Minnesota
1:10-1:55 pm	LUNCH
1:55-5:00 pm	SYMPOSIUM 6

1:55-2:35 pm	ALIGN Improving Emergency Department Care of VOE by Embedding Individualized Pain Plans in the Electronic Health Record for Providers AND Patients: A Report from the ALIGN Trial Dr. Allison King, Washington University COMPARE A Comparison of Patient Specific vs. Weight Based Opioid Pain Plans to Treat VOE in the ED: Results From the COMPARE-VOE Trial Dr. Paula Tanabe, Duke University
2:35-2:55 pm	Prevalence and Risk Factors of Thromboembolism in Women with Sickle Cell Disease During Pregnancy Dr. Shreya Agarwal, University of California San Francisco
2:55-3:15 pm	Sickle Cell Disease Treatment with Arginine Therapy (STArT) Dr. Claudia R. Morris, Emory University
3:15-3:35 pm	Emerging Therapeutics for Sickle Cell Disease Dr. Modupe Idowu, UTHealth Houston McGovern Medical School
3:35-3:45 pm	BREAK
3:45-4:05 pm	PhenX toolkit: a Resource for Sickle Cell Disease Research Dr. Wayne Huggins, RTI International Dr. Carol Hamilton, RTI International
4:05-4:50 pm	Sickle Cell Data Collection Updates Dr. Mary Hulihan, Center for Disease Control and Prevention Sickle Cell Data Collection Program: Overview, Approach, and Progress Dr. Matt Smeltzer, The University of Memphis Pregnancy And Disease-Related Morbidity Among Medicaid Enrollees With Sickle Cell Disease Dr. Mariam Kayle, Duke University School of Nursing The Impact of COVID-19 on People With Sickle Cell Disease Dr. Sarah Reeves, Susan B. Meister Child Health Evaluation and Research Center (CHEAR), University of Michigan Sickle Cell Data Collection Program: Moving Forward Dr. Mary Hulihan, Centers for Disease Control and Prevention, Division of Blood Disorders
4:40-4:50 pm	Q & A
4:50-5:00 pm	Closing Remarks
5:00 pm	MEETING ADJOURN